Xiaojun Tang1, Linyu Geng1, Xuebing Feng1, Lingyun Sun1. 1. Department of Rheumatology and Immunology, Nanjing University Medical School Affiliated Drum Tower Hospital, Nanjing, China.
Abstract
OBJECTIVE: To evaluate serum concentration and activity of angiotensin-converting enzyme 2 (ACE2) in patients with connective tissue diseases (CTDs). METHODS: Serum samples from healthy subjects and patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), primary Sjögren's syndrome (SS) and rheumatoid arthritis (RA) were collected. The concentration and activity of ACE2 were measured by ELISA and fluorometric method respectively, and analyzed for associations with clinical features and concurrent medications. RESULTS: Totally 66 SLE, 55 SSc, 31 SS and 31 RA patients were involved. ACE2 concentration was significantly decreased in patients with either of the four CTDs compared with healthy subjects. The concentration was not linked to special clinical features expect that it was slightly lower in patients with lupus nephritis than those without. In SLE patients, ACE2 concentration elevated with the increase of glucocorticoids, and was not associated with other treatments. Different from the concentration, ACE2 activity was increased in CTD patients. A weak correlation of ACE2 activity with SLE disease activity index score was also observed. CONCLUSION: The clinical significance of ACE2 concentration and activity looks quite different among CTD patients. Preliminary data suggests ACE2 levels are not affected by most of the treatments.
OBJECTIVE: To evaluate serum concentration and activity of angiotensin-converting enzyme 2 (ACE2) in patients with connective tissue diseases (CTDs). METHODS: Serum samples from healthy subjects and patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), primary Sjögren's syndrome (SS) and rheumatoid arthritis (RA) were collected. The concentration and activity of ACE2 were measured by ELISA and fluorometric method respectively, and analyzed for associations with clinical features and concurrent medications. RESULTS: Totally 66 SLE, 55 SSc, 31 SS and 31 RApatients were involved. ACE2 concentration was significantly decreased in patients with either of the four CTDs compared with healthy subjects. The concentration was not linked to special clinical features expect that it was slightly lower in patients with lupus nephritis than those without. In SLEpatients, ACE2 concentration elevated with the increase of glucocorticoids, and was not associated with other treatments. Different from the concentration, ACE2 activity was increased in CTD patients. A weak correlation of ACE2 activity with SLE disease activity index score was also observed. CONCLUSION: The clinical significance of ACE2 concentration and activity looks quite different among CTD patients. Preliminary data suggests ACE2 levels are not affected by most of the treatments.
Authors: Boglárka Soós; Miklós Fagyas; Ágnes Horváth; Edit Végh; Anita Pusztai; Monika Czókolyová; Alexandra Csongrádi; Attila Hamar; Zsófia Pethő; Nóra Bodnár; György Kerekes; Katalin Hodosi; Éva Szekanecz; Szilvia Szamosi; Sándor Szántó; Gabriella Szűcs; Zoltán Papp; Zoltán Szekanecz Journal: Front Med (Lausanne) Date: 2022-01-27
Authors: Regina Larionova; K Byvaltsev; Оlga Kravtsova; Elena Takha; Sergei Petrov; Gevorg Kazarian; Anna Valeeva; Eduard Shuralev; Malik Mukminov; Yves Renaudineau; Marina Arleevskaya Journal: J Transl Autoimmun Date: 2022-04-12